Spectrophotometric Determination of Phenylephrine Hydrochloride in Pharmaceutical Formulations Using an Oxidative Coupling Reaction

Taher Mahmood Hussein; Shahla Jamal Shakkor

doi:10.51699/cajmns.v6i4.2946

Taher Mahmood Hussein Department of Chemistry, College of Sciences, University of Kirkuk, Kirkuk, Iraq
Shahla Jamal Shakkor Department of Chemistry, College of Sciences, University of Kirkuk, Kirkuk, Iraq

DOI: https://doi.org/10.51699/cajmns.v6i4.2946

Keywords: Oxidative Coupling Reaction, p-Aminophenol, Potassium Iodate, Phenylephrine Hydrochloride

Abstract

This study presents a simple and accurate analytical method for the quantitative determination of selected decongestants and cough suppressants, specifically phenylephrine hydrochloride, in both pure form and pharmaceutical formulations. The method is based on an oxidative coupling reaction with p-aminophenol using potassium iodate as an oxidizing agent in a hydrochloric acid medium. Key experimental parameters including reagent concentrations, acid strength, temperature, reaction time, and stability were thoroughly investigated and optimized. The developed method demonstrated excellent linearity in the range of 5–50 µg/mL at a wavelength of 548 nm, with high precision, accuracy, and sensitivity evidenced by a low limit of detection (LOD) of 0.1207 µg/mL and a limit of quantitation (LOQ) of 0.3659 µg/mL . Successful application to a commercial syrup formulation yielded high recovery percentages, confirming the method's accuracy and revealing no significant interference from common excipients. Consequently, this proposed method is straightforward, cost-effective, and highly suitable for routine quality control analysis in pharmaceutical laboratories.

References

United States Pharmacopeia and National Formulary (USP 46-NF 41), United States Pharmacopeial Convention, 2023.

British Pharmacopoeia Commission, British Pharmacopoeia 2024, Norwich, England: Stationery Office Books, 2024.

G. K. Rakam, A. Mallik, C. H. Sucharitha, "Method development and validation of reverse phase high performance liquid chromatography method for estimation of ondansetron and pantoprazole in their tablet dosage form," Indian J. Pharm. Sci., vol. 84, no. 2, pp. 483-492, 2022.

A. M. Abass, S. S. Alabdullah, O. S. Hassan, A. Ahmed, "Novel potentiometric sensors for determination of ondansetron hydrochloride in pure and dosage form," RSC Advances, vol. 11, no. 55, pp. 34820-34827, 2021.

M. M. Rasheedy, M. M. El-Mahdy, D. Fathallah, E. A. Ibrahim, "Formulation and evaluation of ondansetron transdermal gels," Bull. Pharm. Sci., Assiut University, vol. 40, no. 1, pp. 57-70, 2017.

M. A. Abdel Rahman, S. A. Atty, S. S. El-Mosallamy, M. R. Elghobashy, H. E. Zaazaa, A. S. Saad, "Experimentally designed electrochemical sensor for therapeutic drug monitoring of Ondansetron co-administered with chemotherapeutic drugs," BMC Chemistry, vol. 16, no. 1, p. 77, 2022.

Y. Mou, W. Zhao, W. Pan, X. Li, M. Sun, Y. Bo, Y. Zhao, Y. Hu, J. Peng, C. Deana, A. Kaserer, "A comparison of ondansetron in preventing postoperative nausea and vomiting for patients with or without preoperative anxiety with painless egg retrieval: a prospective, randomized, controlled trial," Gland Surgery, vol. 13, no. 8, pp. 1522-1534, 2024.

A. A. Shama, A. A. Elsayed, A. A. Albraithen, S. K. Arafa, "Effect of dexmedetomidine, dexamethasone, and ondansetron on postoperative nausea and vomiting in children undergoing dental rehabilitation: a randomized controlled trial," Pain Physician, vol. 26, no. 1, pp. 1-11, 2023.

J. Kaur, A. Lenka, J. R. Isaacson, S. H. Isaacson, "Ondansetron for the treatment of Parkinson’s disease psychosis: rationale and literature review," Annals of Movement Disorders, vol. 6, no. 2, pp. 72-78, 2023.

C. Kwan, I. Frouni, D. Bédard, A. Hamadjida, P. Huot, "Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease," Eur. J. Pharmacol., vol. 871, p. 172914, 2020.

S. Zhang, Y. Ma, "Emerging role of psychosis in Parkinson's disease: from clinical relevance to molecular mechanisms," World J. Psychiatry, vol. 12, no. 9, pp. 1127-1140, 2022.

S. N. Gayatri, K. Palle, T. Susmitha, S. Yumnam, N. P. Kumar, "Spectrofluorimetric determination of ondansetron in pharmaceutical tablets: applicability to human urine and content uniformity testing," Materials Today: Proceedings, vol. 64, pp. 79-82, 2022.

P. L. Shirole, D. P. Sanap, K. R. Jadhav, "Development and validation of a UV spectrophotometric method for determination of ondansetron hydrochloride in bulk and tablet dosage form," Res. J. Pharm. Technol., vol. 17, no. 3, pp. 1061-1064, 2024.

P. Shirole, D. Sanap, K. Jadhav, "Development and validation of Q-absorbance ratio spectrophotometric method for simultaneous estimation of ondansetron HCl and esomeprazole magnesium in bulk and formulation," J. Res. Pharm., vol. 27, no. 6, pp. 2522-2529, 2023.

V. M. Biju, S. N. Gayatri, A. S. Thomas, "A UV spectrophotometric assay method for available brands of ondansetron hydrochloride," World J. Pharm. Pharm. Sci., vol. 6, no. 7, pp. 820-827, 2022.

U. P. Panigrahy, S. P. Panda, B. K. Dey, "A novel analytical approach for simultaneous estimation of esomeprazole and ondansetron by HPLC-DAD method with degradation studies," Res. J. Pharm. Technol., vol. 16, no. 10, pp. 4855-4860, 2023.

S. J. Shakkor, N. Mohammed, S. R. Shakor, "Spectrophotometric method for determination of methyldopa in bure and pharmaceutical formulation based on oxidative coupling reaction," Chemical Methodologies, vol. 6, no. 11, pp. 851-860, 2022.

A. M. K. Ahmed, S. J. Shakkor, "Determination of amoxicillin in pharmaceutical preparations by spectrophotometric and flow injection–activated chemiluminescence methods," Tikrit J. Pharm. Sci., vol. 14, no. 1, pp. 63-79, 2019.